Johnson & Johnson (NYSE:JNJ) Shares Purchased by WESPAC Advisors SoCal LLC

WESPAC Advisors SoCal LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 72,668 shares of the company’s stock after acquiring an additional 1,015 shares during the period. Johnson & Johnson accounts for 3.8% of WESPAC Advisors SoCal LLC’s portfolio, making the stock its 6th largest position. WESPAC Advisors SoCal LLC’s holdings in Johnson & Johnson were worth $11,596,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Amundi acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at $911,021,000. Franklin Resources Inc. grew its holdings in shares of Johnson & Johnson by 15.8% in the 2nd quarter. Franklin Resources Inc. now owns 16,118,269 shares of the company’s stock valued at $2,655,321,000 after buying an additional 2,197,757 shares during the period. State Street Corp grew its holdings in shares of Johnson & Johnson by 1.3% in the 2nd quarter. State Street Corp now owns 142,047,884 shares of the company’s stock valued at $23,400,968,000 after buying an additional 1,777,289 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Johnson & Johnson by 25,239.1% in the 2nd quarter. Renaissance Technologies LLC now owns 1,748,400 shares of the company’s stock valued at $288,031,000 after buying an additional 1,741,500 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 231,432,368 shares of the company’s stock valued at $38,126,168,000 after buying an additional 1,701,721 shares during the period. 67.14% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on JNJ shares. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 price objective on the stock in a research report on Friday, October 22nd. Morgan Stanley cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective on the stock. in a research report on Tuesday, September 7th. Raymond James cut their price objective on shares of Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 20th. SVB Leerink reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Finally, Wells Fargo & Company reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, October 7th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $187.78.

NYSE:JNJ traded down $0.45 on Thursday, hitting $160.24. 5,230,043 shares of the company’s stock were exchanged, compared to its average volume of 7,039,470. The firm has a 50-day moving average price of $162.64 and a 200-day moving average price of $167.35. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.34 and a quick ratio of 1.11. Johnson & Johnson has a 52 week low of $142.86 and a 52 week high of $179.92. The company has a market cap of $421.85 billion, a P/E ratio of 23.95, a price-to-earnings-growth ratio of 2.38 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Monday, October 18th. The company reported $2.60 earnings per share for the quarter, topping the consensus estimate of $2.35 by $0.25. The company had revenue of $23.34 billion for the quarter, compared to analyst estimates of $23.72 billion. Johnson & Johnson had a net margin of 19.55% and a return on equity of 37.90%. Johnson & Johnson’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.20 EPS. On average, research analysts expect that Johnson & Johnson will post 9.78 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 7th. Stockholders of record on Tuesday, November 23rd will be paid a dividend of $1.06 per share. The ex-dividend date of this dividend is Monday, November 22nd. This represents a $4.24 annualized dividend and a dividend yield of 2.65%. Johnson & Johnson’s dividend payout ratio is presently 63.38%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Story: How do taxes affect a CDs total return?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.